ATE536355T1 - 3,3-spiroindolinionderivate als antikrebsmittel - Google Patents

3,3-spiroindolinionderivate als antikrebsmittel

Info

Publication number: ATE536355T1
Authority: AT; Austria
Prior art keywords: spiroindolinion; derivatives; anticancer agents; anticancer; agents
Prior art date: 2007-05-17

Application number

AT08750071T

Other languages

English (en)

Inventor

Jin-Jun Liu

Jefferson Wright Tilley

Zhuming Zhang

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-17

Filing date

2008-05-06

Publication date

2011-12-15

2008-05-06 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE536355T1 publication Critical patent/ATE536355T1/de

Links

239000002246 antineoplastic agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

AT08750071T 2007-05-17 2008-05-06 3,3-spiroindolinionderivate als antikrebsmittel ATE536355T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US93849407P	2007-05-17	2007-05-17
PCT/EP2008/055516 WO2008141917A1 (en)	2007-05-17	2008-05-06	3,3-spiroindolinone derivatives

Publications (1)

Publication Number	Publication Date
ATE536355T1 true ATE536355T1 (de)	2011-12-15

Family

ID=39645551

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08750071T ATE536355T1 (de)	2007-05-17	2008-05-06	3,3-spiroindolinionderivate als antikrebsmittel

Country Status (16)

Country	Link
US (1)	US7553833B2 (de)
EP (1)	EP2158205B1 (de)
JP (1)	JP2010527340A (de)
KR (1)	KR101162518B1 (de)
CN (1)	CN101679446B (de)
AR (1)	AR066583A1 (de)
AT (1)	ATE536355T1 (de)
AU (1)	AU2008253154A1 (de)
BR (1)	BRPI0811718A2 (de)
CA (1)	CA2686675A1 (de)
ES (1)	ES2377245T3 (de)
IL (1)	IL201973A0 (de)
MX (1)	MX2009012345A (de)
PE (1)	PE20090279A1 (de)
TW (1)	TW200906832A (de)
WO (1)	WO2008141917A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7638548B2 (en) *	2006-11-09	2009-12-29	Hoffmann-La Roche Inc.	Spiroindolinone derivatives
US7723372B2 (en)	2008-03-19	2010-05-25	Hoffman-La Roche Inc.	Spiroindolinone derivatives
US20100190814A1 (en) *	2009-01-26	2010-07-29	Li Chen	Spiroindolinone derivative prodrugs
US7928233B2 (en) *	2009-02-10	2011-04-19	Hoffmann-La Roche Inc.	Spiroindolinone pyridine derivatives
US8217051B2 (en) *	2009-02-17	2012-07-10	Hoffmann-La Roche Inc.	Spiroindolinone derivatives
US8076482B2 (en)	2009-04-23	2011-12-13	Hoffmann-La Roche Inc.	3,3′-spiroindolinone derivatives
UA107814C2 (uk) *	2009-11-12	2015-02-25	Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган	Спірооксіндольні антагоністи мdм2
US8088815B2 (en) *	2009-12-02	2012-01-03	Hoffman-La Roche Inc.	Spiroindolinone pyrrolidines
US8288431B2 (en) *	2010-02-17	2012-10-16	Hoffmann-La Roche Inc.	Substituted spiroindolinones
US8217044B2 (en)	2010-04-28	2012-07-10	Hoffmann-La Roche Inc.	Spiroindolinone pyrrolidines
JP2014500870A (ja)	2010-11-12	2014-01-16	ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン	スピロ−オキシインドールｍｄｍ２アンタゴニスト
SG193002A1 (en)	2011-03-10	2013-09-30	Daiichi Sankyo Co Ltd	Dispiropyrrolidine derivative
WO2012155066A2 (en)	2011-05-11	2012-11-15	Shaomeng Wang	Spiro-oxindole mdm2 antagonists
TWI586668B (zh)	2012-09-06	2017-06-11	第一三共股份有限公司	二螺吡咯啶衍生物之結晶
KR102196882B1 (ko)	2012-12-20	2020-12-30	머크 샤프 앤드 돔 코포레이션	Hdm2 억제제로서의 치환된 이미다조피리딘
CN103992334A (zh) *	2014-05-29	2014-08-20	中国人民解放军第二军医大学	吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法
WO2016001376A1 (en)	2014-07-03	2016-01-07	Boehringer Ingelheim International Gmbh	New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
RS59111B1 (sr)	2014-08-21	2019-09-30	Boehringer Ingelheim Int	Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
CA2976752C (en)	2015-02-20	2019-12-17	Daiichi Sankyo Company, Limited	Method for treating cancer by combined use
CN105541716B (zh)	2015-03-26	2024-02-23	Ａｇｃ株式会社	吡唑衍生物的制造方法
JP6823587B2 (ja)	2015-04-13	2021-02-03	第一三共株式会社	Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
KR20240158360A (ko)	2015-10-09	2024-11-04	베링거 인겔하임 인터내셔날 게엠베하	Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
US10759808B2 (en)	2016-04-06	2020-09-01	The Regents Of The University Of Michigan	Monofunctional intermediates for ligand-dependent target protein degradation
SG11201808728QA (en)	2016-04-06	2018-11-29	Univ Michigan Regents	Mdm2 protein degraders
CN118436801A (zh)	2016-05-20	2024-08-06	豪夫迈·罗氏有限公司	Protac抗体缀合物及其使用方法
EP3527226A4 (de)	2016-10-17	2020-06-17	Daiichi Sankyo Company, Limited	Kombinationstherapieverfahren mit mdm2-inhibitor und dna-methyltransferase-inhibitor
CN107337638A (zh) *	2017-08-14	2017-11-10	侯茜茜	一种吡啶甲酸类食品添加剂的高效合成方法
CN112912143A (zh)	2018-10-08	2021-06-04	美国密歇根州立大学试剂中心	小分子mdm2蛋白降解剂
KR20230005160A (ko)	2020-03-19	2023-01-09	카이메라 쎄라퓨틱스 인코포레이티드	Mdm2 분해제 및 이의 용도
WO2023056069A1 (en)	2021-09-30	2023-04-06	Angiex, Inc.	Degrader-antibody conjugates and methods of using same
CN116496281B (zh) *	2022-12-30	2025-05-13	重庆文理学院	一种苯并氮卓螺二氢吲哚化合物及其合成方法与应用
WO2024240858A1 (en)	2023-05-23	2024-11-28	Valerio Therapeutics	Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2098212B (en) *	1981-05-12	1984-11-14	Ici Plc	Process for preparing 1'-substituted-spiro(imidazolidine)-4,3'-indoline-2,2',5-triones
EP0947511A1 (de)	1998-03-30	1999-10-06	F. Hoffmann-La Roche Ag	Phenoxy-Essigsäurederivate und Phenoxymetyl-Tetrazolderivate mit antitumoraler Wirkung
AR056968A1 (es) *	2005-04-11	2007-11-07	Xenon Pharmaceuticals Inc	Compuestos espiro-oxindol y composiciones farmacéuticas
US20070213341A1 (en) *	2006-03-13	2007-09-13	Li Chen	Spiroindolinone derivatives

2008
- 2008-04-11 US US12/101,182 patent/US7553833B2/en not_active Expired - Fee Related
- 2008-05-06 KR KR1020097023637A patent/KR101162518B1/ko not_active Expired - Fee Related
- 2008-05-06 MX MX2009012345A patent/MX2009012345A/es active IP Right Grant
- 2008-05-06 EP EP08750071A patent/EP2158205B1/de not_active Not-in-force
- 2008-05-06 AT AT08750071T patent/ATE536355T1/de active
- 2008-05-06 ES ES08750071T patent/ES2377245T3/es active Active
- 2008-05-06 AU AU2008253154A patent/AU2008253154A1/en not_active Abandoned
- 2008-05-06 JP JP2010507884A patent/JP2010527340A/ja active Pending
- 2008-05-06 CA CA002686675A patent/CA2686675A1/en not_active Abandoned
- 2008-05-06 CN CN2008800164254A patent/CN101679446B/zh not_active Expired - Fee Related
- 2008-05-06 BR BRPI0811718-7A2A patent/BRPI0811718A2/pt not_active IP Right Cessation
- 2008-05-06 WO PCT/EP2008/055516 patent/WO2008141917A1/en not_active Ceased
- 2008-05-14 TW TW097117735A patent/TW200906832A/zh unknown
- 2008-05-14 PE PE2008000842A patent/PE20090279A1/es not_active Application Discontinuation
- 2008-05-15 AR ARP080102062A patent/AR066583A1/es unknown
2009
- 2009-11-05 IL IL201973A patent/IL201973A0/en unknown

Also Published As

Publication number	Publication date
PE20090279A1 (es)	2009-04-02
KR101162518B1 (ko)	2012-07-09
US20080287421A1 (en)	2008-11-20
IL201973A0 (en)	2010-06-16
AR066583A1 (es)	2009-09-02
BRPI0811718A2 (pt)	2014-11-18
AU2008253154A1 (en)	2008-11-27
TW200906832A (en)	2009-02-16
EP2158205B1 (de)	2011-12-07
KR20090130312A (ko)	2009-12-22
WO2008141917A1 (en)	2008-11-27
JP2010527340A (ja)	2010-08-12
CN101679446A (zh)	2010-03-24
US7553833B2 (en)	2009-06-30
CA2686675A1 (en)	2008-11-27
EP2158205A1 (de)	2010-03-03
MX2009012345A (es)	2009-12-01
ES2377245T3 (es)	2012-03-23
CN101679446B (zh)	2012-06-27

Publication	Publication Date	Title
ATE536355T1 (de)	2011-12-15	3,3-spiroindolinionderivate als antikrebsmittel
ATE555107T1 (de)	2012-05-15	2-aza-bicyclo-ä2,2,1-üheptan-derivate
DE602008005634D1 (de)	2011-04-28	1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0907563A2 (pt)	2015-08-04	Derivados de 4,5-di-hidro-xazol-2-il amina
LT3492069T (lt)	2022-04-11	Farmacinės kompozicijos, apimančios geležies oksihidroksidą
BRPI0816970A2 (pt)	2015-03-24	1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
ATE481383T1 (de)	2010-10-15	3-aza-bicycloä3.1.0ühexanderivate
ATE469145T1 (de)	2010-06-15	4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
ATE540040T1 (de)	2012-01-15	Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
HRP20151058T1 (xx)	2015-12-04	Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
BRPI1006113A2 (pt)	2016-02-16	"derivado de piridina".
BRPI0923047A2 (pt)	2015-12-08	"conjugados de proteínas-oligossacarídeos".
BRPI0810646A2 (pt)	2014-11-04	" compostos farmacêuticos ".
EP2291078A4 (de)	2011-08-24	Oxazolbenzimidazolderivate
BRPI1008899A2 (pt)	2018-03-13	derivados 3,3´-espiroindolinona como agentes anticâncer
BRPI0716046A2 (pt)	2013-09-17	composiÇÕes de nanopartÍcula.
EP2279532A4 (de)	2011-07-27	Oxazolbenzimidazolderivate
DE602007001681D1 (de)	2009-09-03	1,3-dioxan-carboxylsäuren
BRPI0923048A2 (pt)	2018-09-25	"composto de aminopirazol".
BRPI0815059A2 (pt)	2015-02-10	Derivado de 1,3-di-hidroisoindol
BRPI0916363A2 (pt)	2018-05-29	derivados de 4,5-di-hidro-oxazol-2-ila
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
EP2365820A4 (de)	2013-01-16	Endothel-simulierende nanomatrix
BRPI0906714A2 (pt)	2015-06-30	Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI0816679A2 (pt)	2015-03-17	Derivados de ftalazinona.